Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer-Reference-Cited by-同舟云学术

Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer

Published:2024-01 Issue:1 Volume:3 Page:
ISSN:2766-5526
Container-title:NEJM Evidence
language:en
Short-container-title:NEJM Evidence

Author:

Fizazi Karim¹,Bernard-Tessier Alice¹,Roubaud Guilhem²,Utriainen Tapio³,Barthélémy Philippe⁴,Fléchon Aude⁵,van der Voet Johannes⁶,Gravis Gwenaëlle⁷,Ratta Raffaele⁸,Jones Robert⁹,Parikh Omi¹⁰,Tanner Minna¹¹,Antonarakis Emmanuel S.¹²,Baldini Capucine¹³,Peters Niamh¹⁴,Garratt Chris¹⁵,Ikonen Tarja¹⁵,Pohjanjousi Pasi¹⁵,Joensuu Heikki¹⁵,Cook Natalie¹⁴

Affiliation:

1. Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France

2. Medical Oncology, Institut Bergonié, Bordeaux, France

3. Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland

4. Institut de Cancérologie Strasbourg Europe, Strasbourg, France

5. Medical Oncology, Centre Léon Bérard, Lyon, France

6. Radiotherapy, The James Cook University Hospital, Middlesbrough, United Kingdom

7. Medical Oncology, Institut Paoli-Calmettes, Marseille, France

8. Medical Oncology, Hôpital Foch, Suresnes, France

9. Cardiff University and Velindre University National Health Service Trust, Cardiff, United Kingdom

10. Oncology, Royal Preston Hospital–Lancashire Teaching Hospitals National Health Service Foundation Trust, Preston, United Kingdom

11. R&D, Tampere University Hospital, Tampere, Finland

12. Department of Medicine, University of Minnesota Masonic Cancer Center, Minneapolis

13. Drug Development Department, Université Paris-Saclay, Gustave Roussy, Villejuif, France

14. University of Manchester and the Christie National Health Service Foundation Trust, Manchester, United Kingdom

15. Orion Corporation, Orion Pharma, Espoo, Finland

Publisher

Massachusetts Medical Society

Reference24 articles.

1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): prostate cancer. January 2023(https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf).

2. Mottet N Cornford P Van den Bergh RCN et al. EAU–EANM–ESTRO–ESUR–ISUP–SIPG guidelines on prostate cancer. March 2022 (https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-EANM-ESTRO-ESUR-ISUP_SIOG-Guidelines-on-Prostate-Cancer-2022_2022-04-25-063938_yfos.pdf).

3. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

4. Comparison of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Failure: A Systematic Review and Network Meta-analysis

5. Recent Advances in the Management of Metastatic Prostate Cancer

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives;Clinical Genitourinary Cancer;2024-10

2. Re: Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer;European Urology;2024-08

3. Targeting Androgen Receptor Alterations in Metastatic Prostate Cancer;European Urology Focus;2024-08

4. The Evidence Is In;NEJM Evidence;2024-03-26

5. Statistics of Rare Events;NEJM Evidence;2023-12-26